Shingo Asahara

Summary

Publications

  1. doi request reprint Phase I/II clinical trial using HLA-A24-restricted peptide vaccine derived from KIF20A for patients with advanced pancreatic cancer
    Shingo Asahara
    Department of Internal Medicine, Chiba Tokushukai Hospital, Chiba, Japan
    J Transl Med 11:291. 2013

Detail Information

Publications1

  1. doi request reprint Phase I/II clinical trial using HLA-A24-restricted peptide vaccine derived from KIF20A for patients with advanced pancreatic cancer
    Shingo Asahara
    Department of Internal Medicine, Chiba Tokushukai Hospital, Chiba, Japan
    J Transl Med 11:291. 2013
    ..In this report, we further demonstrated non-randomized, open-label, single centered phase I/II clinical trial of immunotherapy using the KIF20A-66 peptide for the patients with advanced pancreatic cancer...